Asahi Kasei pushes into human trials with new autoimmune drug candidate
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Subscribe To Our Newsletter & Stay Updated